+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Large Volume Wearable Injectors Market (5th Edition), 2020-2030: Focus on Bolus, Basal and Continuous Delivery Devices

  • ID: 5093929
  • Report
  • May 2020
  • Region: Global
  • 550 Pages
  • Roots Analysis
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • 3M
  • BeiGene
  • EMD Serono
  • Ipsen
  • Novo Nordisk
  • Selexys Pharmaceuticals
  • MORE

Overview

Chronic diseases, such as diabetes, cardiovascular disorders, neurological disorders, autoimmune disorders and various types of cancer, are known to be the leading causes of death and disability across the world. The clinical conditions associated with these diseases affect patients’ overall quality of life. In fact, according to the World Health Organization (WHO), over 50% of the global population is currently estimated to be suffering from at least one chronic disease. The past few years have witnessed introduction of several innovative pharmaceutical interventions for the treatment of a number of such diseases. However, majority of the available treatment options require parenteral administration of the drug, frequent dosing, and involve repeated hospital visits.

Treatment administration via the parenteral route is also associated with various concerns, such as dosing errors, risk of microbial contamination and needlestick injuries. These are known to be the primary factors affecting medication adherence and, thereby, have a significant impact on therapeutic outcomes. Over the past few years, a number of companies have developed advanced therapeutic delivery solutions (such as autoinjectors, pen injectors, prefilled syringes) to overcome the challenges associated with the administration of both conventional and novel drug/therapy molecules. In fact, these drug delivery devices can prove to be potential vehicles for drug administration in disease outbreaks/pandemics (such as the one being faced due to the novel corona virus/COVID-19). Amongst modern drug delivery practices, the concept of self-injection has facilitated the administration of medications outside the clinical setting. Such practices also allow reductions in healthcare costs and enable the optimal usage of healthcare resources.

Specifically, large volume wearable injectors used for subcutaneous drug delivery, have become a preferred choice for administration of drugs in the home-care setting. Variants of these wearable devices have been designed to administer highly viscous drugs (such as biologics) in large volumes (more than 1 mL), offering numerous dosing options (basal, bolus or continuous), integrated safety mechanisms, and an almost negligible risk of needlestick injuries. Such devices have captured the interest of several stakeholders in this industry and are being used for the administration of both insulin and non-insulin drugs. The field is presently witnessing a lot of innovation, such as the development of integrated mobile applications with smart health monitoring, artificial intelligence algorithms and other interesting features (including provisions for reminders, and the ability to connect to web-based portals for sharing medical data with the concerned healthcare providers), visual/audible drug delivery confirmation notifications, automatic drug reconstitution, and error alerts. We believe that such efforts are likely to drive growth in this market over the coming years.

Scope of the Report

The “Large Volume Wearable Injectors Market (5th Edition), 2020-2030: Focus on Bolus , Basal and Continuous Delivery Devices” report features an extensive study of the current market landscape and the likely future evolution of these self-injection devices, over the next ten years. It specifically lays emphasis on the emergence of patient-centric, convenient, cost-effective and user-friendly wearable drug delivery solutions that are capable of administering large volumes of a drug subcutaneously, in the home-care setting.

Amongst other elements, the report includes:

  • An overview of current market landscape of the large volume wearable injectors available for delivery of insulin and non-insulin drugs, providing information on status of development and device specifications, such as type of device (patch pump/injector and infusion pump/injector), type of dose administered (basal, bolus and others), route of administration (subcutaneous and others), mode of injection (needle, needle/cannula and needle/catheter), storage capacity of the device, actuation mechanism (electromechanical, rotary pump, cell/expanded battery, pressurized gas, osmotic pressure and others), usability (disposable and reusable), availability of prefilled drug reservoir and availability of device connectivity. The report also features additional information on availability of prefilled insulin cartridges, availability of continuous glucose monitoring/blood glucose monitoring (CGM/BGM) systems, availability of Automated Insulin Delivery feature and type of remote control features (control within device/personal diabetes manager (PDM)/smartphone) in the insulin delivery devices.  
  • A detailed competitiveness analysis of large volume wearable injectors based on various relevant parameters, such as supplier power (based on the experience/expertise of the developer) and product specifications (type of device, type of dose, storage capacity of the device, usability, route of administration, connectivity and availability of a continuous glucose monitoring/blood glucose monitoring (CGM/BGM) systems (in case of insulin devices).
  • Elaborate profiles of the prominent companies that develop large volume wearable injectors. Each company profile features a brief overview of the company, its financial information (if available), information on its product portfolio, recent developments and an informed future outlook. Additionally, the report includes tabulated profiles of wearable drug device combination products.
  • An analysis of the partnerships that have been inked by the stakeholders in this domain, during the period between 2015 and 2020, covering acquisitions, product development agreements, product integration agreements, technology integration agreements, distribution and supply agreements, commercialization agreements, clinical trial agreements, licensing agreements, manufacturing agreements,  service agreements, and other relevant types of deals.
  • A detailed analysis on acquisition targets, taking into consideration the historical trend of the activity of the companies that have acquired other firms since 2000, and offering a means for other industry stakeholders to identify potential acquisition targets.
  • An in-depth analysis of the various patents that have been submitted/filed related to large volume wearable injectors over the last three decades. It also highlights the key parameters associated with the patents, including information on patent type, issuing authority/patent offices involved, Cooperative Patent Classification (CPC) symbols, emerging areas (in terms of number of patents filed/granted), company type and leading industry, non-industry and individual patent assignees (in terms of size of intellectual property portfolio).
  • A list of marketed drugs/therapies and pipeline candidates that are likely to be developed in combination with large volume wearable injectors in the near future, identified on the basis of an in-depth analysis of potential candidates, taking into consideration multiple parameters, such as stage of development, dosage, dose concentration, route of administration, type of dose and drug sales (in case of marketed drugs).
  • A social media analysis depicting prevalent and emerging trends, and the popularity of large volume wearable injectors, as observed on the social media platform, Twitter. The analysis was based on tweets posted on the platform in the last few years.
  • A detailed analysis of completed, ongoing and planned clinical trials of various large volume wearable injector products based on the various relevant parameters, such as trial registration year, current trial phase, trial status, study design, study focus, targeted therapeutic area and clinical outcomes.
  • A case study on the role of contract manufacturing organizations in the overall manufacturing process/supply chain of wearable injectors. It includes information on the services provided by contract service providers for manufacturing of various device components (primary containers), infusion sets, adhesives, closures and injection moldings.
  • An elaborate discussion on the various guidelines established by major regulatory bodies for medical device approval across North America (the US, Canada and Mexico), Europe (the UK, France, Germany, Italy, Spain and rest of Europe), Asia-Pacific and rest of the world (Australia, Brazil, China, India, Israel, Japan, New Zealand, Singapore, South Africa, South Korea, Taiwan, and Thailand). The report also features an insightful multi-dimensional, heat map analysis, featuring a comparison of the contemporary regulatory and reimbursement scenarios in key geographies across the globe.

One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities for large volume wearable injectors. Based on parameters, such as the number of commercialized devices, number of devices under development, price of the device and the annual adoption rate, we have provided an informed estimate on the likely evolution of the market over the period 2020-2030. The report also features sales forecasts for the overall large volume wearable injectors market with a detailed market segmentation on the [A] type of device (patch pump, injector and infusion pump and injector), [B] usability (reusable and disposable), [C] therapeutic area (neurological disorders, cardiovascular disorders, infectious disease, oncological disorders and others) and [D] key geographies (North America, Europe, Asia Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Mark Banister (CEO, Medipacs/RxActuator)
  • Michael Hooven (CEO, Enable Injections)
  • Jesper Roested (CEO, Subcuject)
  • Pieter Muntendam (former President and CEO, scPharmaceuticals)
  • Menachem Zucker (VP and Chief Scientist, Elcam Medical)
  • Graham Reynolds (VP and GM, Biologics, West Pharmaceutical Services)
  • Mindy Katz (Director of Product, Sorrel Medical)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading large volume wearable device developers?
  • What are the prevalent trends within the competitive landscape of large volume wearable injectors for delivery of non-insulin drugs?
  • What are the prevalent trends within the competitive landscape of large volume wearable injectors for delivery of insulin?
  • What are the types of drug candidates that are suited for delivery via large volume wearable injectors?
  • Who are the key contract service providers involved in this domain?
  • What are medical device regulations across different regions?
  • How is the current and future market opportunity likely to be distributed across key market segments?
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 3M
  • BeiGene
  • EMD Serono
  • Ipsen
  • Novo Nordisk
  • Selexys Pharmaceuticals
  • MORE

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. An Overview of Drug Delivery Devices
3.3. Conventional Parenteral Drug Delivery
3.3.1 Needlestick Injuries
3.3.1.1. Incidence and Cost Burden
3.3.1.2. Prevention of Needlestick Injuries
3.3.1.3. Government Legislations for the Prevention of Needlestick Injuries
3.4. Emergence of Self-Administration Devices
3.4.1. Driving Factors
3.4.1.1. Rising Burden of Chronic Diseases
3.4.1.2. Healthcare Cost Savings
3.4.1.3. Need for Immediate Treatment in Emergency Situations
3.4.1.4. Growing Injectable Drugs Market
3.4.1.5. Rising Focus on Patient Centricity
3.4.1.6. Need for Improving Medication Adherence
3.5. Available Self-Injection Devices
3.5.1. Prefilled Syringes
3.5.2. Pen-Injectors
3.5.3. Autoinjectors
3.5.4. Needle-Free Injectors
3.5.5. Large Volume Wearable Injectors
3.6. Regulatory Considerations
3.6.1. Medical Devices
3.6.2. Drug Device Combinations
3.7. Future Perspectives

4. LARGE VOLUME WEARABLE INJECTORS: CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Large Volume Wearable Injectors: Overall Market Landscape
4.2.1. Large Volume Wearable Injectors for Non-Insulin Drugs: Market Landscape
4.2.1.1. Analysis by Stage of Development
4.2.1.2. Analysis by Type of Device
4.2.1.3. Analysis by Type of Dose
4.2.1.4. Analysis by Route of Administration
4.2.1.5. Analysis by Mode of Injection
4.2.1.6. Analysis by Volume / Storage Capacity
4.2.1.7. Analysis by Actuation Mechanism
4.2.1.8. Analysis by Usability
4.2.1.9. Analysis by Availability of Prefilled Drug Reservoir
4.2.1.10. Analysis by Availability of Connectivity
4.2.2. Large Volume Drug Device Combinations: Market Landscape
4.2.2.1. Analysis by Stage of Development
4.2.2.2. Analysis by Type of Device
4.2.2.3. Analysis by Drug Compatibility
4.2.2.4. Analysis by Type of Dose
4.2.2.5. Analysis by Route of Administration
4.2.2.6. Analysis by Mode of Injection
4.2.2.7. Analysis by Therapeutic Area
4.2.2.8. Analysis by Volume / Storage Capacity
4.2.2.9. Analysis by Usability
4.2.3. Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis of Developers (Devices and Drug Device Combinations)
4.2.3.1. Analysis by Year of Establishment
4.2.3.2. Analysis by Company Size
4.2.3.3. Analysis by Geography
4.2.4. Large Volume Wearable Injectors for Insulin: Market Landscape
4.2.4.1. Analysis by Stage of Development
4.2.4.2. Analysis by Type of Device
4.2.4.3. Analysis by Volume / Storage Capacity
4.2.4.4. Analysis by Usability
4.2.4.5. Analysis by Availability of Prefilled Insulin Cartridges
4.2.4.6. Analysis by Availability of CGM / BGM System
4.2.4.7. Analysis by Availability of Automated Insulin Delivery (AID) Feature
4.2.4.8. Analysis by Availability of Connectivity
4.2.4.9. Analysis by Type of Remote Control Features
4.2.5. Large Volume Wearable Injectors for Insulin: Analysis of Developers
4.2.5.1. Analysis by Year of Establishment
4.2.5.2. Analysis by Company Size
4.2.5.3. Analysis by Geography

5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Product Competitiveness Analysis
5.3.1. Large Volume Wearable Injectors for Non-Insulin Drugs
5.3.2. Large Volume Drug Device Combinations
5.3.3. Large Volume Wearable Injectors for Insulin

6. LARGE VOLUME WEARABLE INJECTORS: KEY PLAYERS
6.1. Chapter Overview
6.2. Large Volume Wearable Injectors for Non-Insulin Drugs: Key Players
6.2.1. Becton Dickinson
6.2.1.1. Company Snapshot
6.2.1.2. Product Portfolio
6.2.1.3. Financial Information
6.2.1.4. Recent Developments and Future Outlook
6.2.2. Bespak
6.2.2.1. Company Snapshot
6.2.2.2. Product Portfolio
6.2.2.3. Financial Information
6.2.2.4. Recent Developments and Future Outlook
6.2.3. Enable Injections
6.2.3.1. Company Snapshot
6.2.3.2. Product Portfolio
6.2.3.3. Recent Developments and Future Outlook
6.2.4. Insulet
6.2.4.1. Company Snapshot
6.2.4.2. Product Portfolio
6.2.4.3. Financial Information
6.2.4.4. Recent Developments and Future Outlook
6.2.5. Roche
6.2.5.1. Company Snapshot
6.2.5.2. Product Portfolio
6.2.5.3. Financial Information
6.2.5.4. Recent Developments and Future Outlook
6.2.6. Sensile Medical
6.2.6.1. Company Snapshot
6.2.6.2. Product Portfolio
6.2.6.3. Recent Developments and Future Outlook
6.2.7. Sonceboz
6.2.7.1. Company Snapshot
6.2.7.2. Product Portfolio
6.2.7.3. Recent Developments and Future Outlook
6.2.8. SteadyMed Therapeutics
6.2.8.1. Company Snapshot
6.2.8.2. Product Portfolio
6.2.8.3. Recent Developments and Future Outlook
6.2.9. Weibel CDS
6.2.9.1. Company Snapshot
6.2.9.2. Product Portfolio
6.2.9.3. Recent Developments and Future Outlook
6.2.10. West Pharmaceutical Services
6.2.10.1. Company Snapshot
6.2.10.2. Product Portfolio
6.2.10.3. Financial Information
6.2.10.4. Recent Developments and Future Outlook
6.3. Large Volume Wearable Injectors for Insulin: Key Players
6.3.1. CeQur
6.3.1.1. Company Snapshot
6.3.1.2. Product Portfolio
6.3.1.3. Recent Developments and Future Outlook
6.3.2. Debiotech
6.3.2.1. Company Snapshot
6.3.2.2. Product Portfolio
6.3.2.3. Recent Developments and Future Outlook
6.3.3. Eli Lilly
6.3.3.1. Company Snapshot
6.3.3.2. Product Portfolio
6.3.3.3. Financial Information
6.3.3.4. Recent Developments and Future Outlook
6.3.4. Medtronic
6.3.4.1. Company Snapshot
6.3.4.2. Product Portfolio
6.3.4.3. Financial Information
6.3.4.4. Recent Developments and Future Outlook
6.3.5. PharmaSens
6.3.5.1. Company Snapshot
6.3.5.2. Product Portfolio
6.3.5.3. Recent Developments and Future Outlook
6.3.6. SOOIL Development
6.3.6.1. Company Snapshot
6.3.6.2. Product Portfolio
6.3.6.3. Recent Developments and Future Outlook
6.3.7. Tandem Diabetes Care
6.3.7.1. Company Snapshot
6.3.7.2. Product Portfolio
6.3.7.3. Financial Information
6.3.7.4. Recent Developments and Future Outlook

7. DRUG-DEVICE COMBINATIONS: TABULATED PROFILES
7.1. Chapter Overview
7.2. Apomorphine / D-mine® Pump
7.3. Apomorphine / ND0701
7.4. Bupivacaine / SMT-301
7.5. Ceftriaxone / sc2Wear® Infusor
7.6. Furosemide / 3 mL Micropump
7.7. Furosemide / FUROSCIX® On-body Infusor
7.8. Herceptin® / Single Use Injector
7.9. Ketorolac / SMT-201
7.10. Levodopa and Carbidopa / ND0612 and ND0901
7.11. Lutrepulse / The LUTREPULSE® System
7.12. Repatha® / Pushtronex® System
7.13. Treprostinil / Trevyent®

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Large Volume Wearable Injectors: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year of Partnership and Type of Partner
8.3.4. Analysis by Type of Partnership and Type of Partner
8.3.5. Most Active Players: Analysis by Number of Partnerships
8.3.6. Regional Analysis
8.3.7. Intercontinental and Intracontinental Agreements

9. KEY ACQUISITION TARGETS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Scoring Criteria and Key Assumptions
9.4. Potential Strategic Acquisition Targets for Non-Insulin Drug Delivery Players
9.5. Potential Strategic Acquisition Targets for Insulin Drug Delivery Players
9.6. Concluding Remarks

10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Large Volume Wearable Injectors: Patent Analysis
10.3.1. Analysis by Publication Year
10.3.2. Analysis by Issuing Authority / Patent Offices Involved
10.3.3. Analysis by CPC Symbols
10.3.4. Emerging Focus Areas
10.3.5. Analysis by Type of Industry
10.3.6. Leading Players: Analysis by Number of Patents
10.4. Large Volume Wearable Injectors: Patent Benchmarking Analysis
10.4.1. Analysis by Patent Characteristics
10.5. Large Volume Wearable Injectors: Patent Valuation Analysis

11. LARGE VOLUME WEARABLE INJECTORS: LIKELY DRUG CANDIDATES
11.1. Chapter Overview
11.2. Marketed Drugs
11.2.1. Most Likely Candidates for Delivery via Large Volume Wearable Injectors
11.2.2. Likely Candidates for Delivery via Large Volume Wearable Injectors
11.2.3. Less Likely Candidates for Delivery via Large Volume Wearable Injectors
11.2.4. Unlikely Candidates for Delivery via Large Volume Wearable Injectors
11.3. Clinical Drug Candidates
11.3.1. Biologics
11.3.1.1. Most Likely Candidates for Delivery via Large Volume Wearable Injectors
11.3.1.2. Likely Candidates for Delivery via Large Volume Wearable Injectors
11.3.1.3. Less Likely Candidates for Delivery via Large Volume Wearable Injectors
11.3.1.4. Unlikely Candidates for Delivery via Large Volume Wearable Injectors
11.3.2. Small Molecules
11.3.2.1. Most Likely Candidates for Delivery via Large Volume Wearable Injectors
11.3.2.2. Likely Candidates for Delivery via Large Volume Wearable Injectors
11.3.2.3. Less Likely Candidates for Delivery via Large Volume Wearable Injectors
11.3.2.4. Unlikely Candidates for Delivery via Large Volume Wearable Injectors

12. EMERGING TRENDS ON SOCIAL MEDIA
12.1. Chapter Overview
12.2. Large Volume Wearable Injectors: Trends on Twitter
12.2.1. Historical Trend in Volume of Tweets
12.2.2. Trending Words / Phrases Related to Large Volume Wearable Injectors
12.2.3. Most Influential Authors
12.2.4. Popular Players on Twitter
12.2.4.1. Roche (Accu-Chek® Solo Micropump System)
12.2.4.2. Insulet (Omnipod®)
12.2.4.3. Medtronic (MiniMed® Wearable Injectors)
12.2.4.4. Comparison of Popular Players Based on Number of Tweets
12.3. Concluding Remarks

13. CLINICAL TRIAL ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Large Volume Wearable Injectors: Clinical Trial Analysis
13.3.1. Analysis by Trial Registration Year
13.3.2. Analysis by Trial Phase
13.3.3. Analysis by Trial Status
13.3.4. Analysis by Study Design
13.3.5. Analysis by Study Focus
13.3.6. Analysis by Target Therapeutic Area
13.3.7. Analysis by Clinical Endpoints

14. CASE STUDY: ROLE OF CMOs IN DEVICE DEVELOPMENT SUPPLY CHAIN
14.1. Chapter Overview
14.2. Device Development Supply Chain
14.3. Significance of CMOs in the Drug Delivery Device Development Process
14.4. List of Contract Manufacturing Organizations
14.4.1. Contract Manufacturers: Geographical Distribution and Services Offered

15. REGULATORY AND REIMBURSEMENT LANDSCAPE FOR MEDICAL DEVICES
15.1. Chapter Overview
15.2. General Regulatory and Reimbursement Guidelines for Medical Devices
15.3. Regulatory and Reimbursement Landscape in North America
15.3.1. The US Scenario
15.3.1.1. Regulatory Authority
15.3.1.2. Review / Approval Process
15.3.1.3. Reimbursement Landscape
15.3.1.3.1. Payer Mix
15.3.1.3.2. Reimbursement Process
15.3.2. The Canadian Scenario
15.3.2.1. Regulatory Authority
15.3.2.2. Review / Approval Process
15.3.2.3. Reimbursement Landscape
15.3.2.3.1. Payer Mix
15.3.2.3.2. Reimbursement Process
15.3.3. The Mexican Scenario
15.3.3.1. Regulatory Authority
15.3.3.2. Review / Approval Process
15.3.3.3. Reimbursement Landscape
15.3.3.3.1. Payer Mix
15.4. Regulatory and Reimbursement Landscape in Europe
15.4.1. Overall Scenario
15.4.1.1. Overall Regulatory Authority
15.4.1.2. Overall Review / Approval Process
15.4.2. The UK Scenario
15.4.2.1. Regulatory Authority
15.4.2.2. Review / Approval Process
15.4.2.3. Reimbursement Landscape
15.4.2.3.1. Payer Mix
15.4.2.3.2. Reimbursement Process
15.4.3. The French Scenario
15.4.3.1. Regulatory Authority
15.4.3.2. Review / Approval Process
15.4.3.3. Reimbursement Landscape
15.4.3.3.1. Payer Mix
15.4.3.3.2. Reimbursement Process
15.4.4. The German Scenario
15.4.4.1. Regulatory Authority
15.4.4.2. Review / Approval Process
15.4.4.3. Reimbursement Landscape
15.4.4.3.1. Payer Mix
15.4.4.3.2. Reimbursement Process
15.4.5. The Italian Scenario
15.4.5.1. Regulatory Authority
15.4.5.2. Review / Approval Process
15.4.5.3. Reimbursement Landscape
15.4.5.3.1. Payer Mix
15.4.5.3.2. Reimbursement Process
15.4.6. The Spanish Scenario
15.4.6.1. Regulatory Authority
15.4.6.2. Review / Approval Process
15.4.6.3. Reimbursement Landscape
15.4.6.3.1. Payer Mix
15.4.6.3.2. Reimbursement Process
15.5. Regulatory and Reimbursement Landscape in Asia-Pacific and Rest of the World
15.5.1. The Australian Scenario
15.5.1.1. Regulatory Authority
15.5.1.2. Review / Approval Process
15.5.1.3. Reimbursement Landscape
15.5.1.3.1. Payer Mix
15.5.1.3.2. Reimbursement Process
15.5.2. The Brazilian Scenario
15.5.2.1. Regulatory Authority
15.5.2.2. Review / Approval Process
15.5.2.3. Reimbursement Landscape
15.5.2.3.1. Payer Mix
15.5.2.3.2. Reimbursement Process
15.5.3. The Chinese Scenario
15.5.3.1. Regulatory Authority
15.5.3.2. Review / Approval Process
15.5.3.3. Reimbursement Landscape
15.5.3.3.1. Payer Mix
15.5.3.3.2. Reimbursement Process
15.5.4. The Indian Scenario
15.5.4.1. Regulatory Authority
15.5.4.2. Review / Approval Process
15.5.4.3. Reimbursement Landscape
15.5.4.3.1. Payer Mix
15.5.5. The Israeli Scenario
15.5.5.1. Regulatory Authority
15.5.5.2. Review / Approval Process
15.5.5.3. Reimbursement Landscape
15.5.5.3.1. Payer Mix
15.5.6. The Japanese Scenario
15.5.6.1. Regulatory Authority
15.5.6.2. Review / Approval Process
15.5.6.3. Reimbursement Landscape
15.5.6.3.1. Payer Mix
15.5.6.3.2. Reimbursement Process
15.5.7. The New Zealand Scenario
15.5.7.1. Regulatory Authority
15.5.7.2. Review / Approval Process
15.5.7.3. Reimbursement Landscape
15.5.7.3.1. Payer Mix
15.5.7.3.2. Reimbursement Process
15.5.8. The Singaporean Scenario
15.5.8.1. Regulatory Authority
15.5.8.2. Review / Approval Process
15.5.8.3. Reimbursement Landscape
15.5.8.3.1. Payer Mix
15.5.8.3.2. Reimbursement Process
15.5.9. The South Korea Scenario
15.5.9.1. Regulatory Authority
15.5.9.2. Review / Approval Process
15.5.9.3. Reimbursement Landscape
15.5.9.3.1. Payer Mix
15.5.9.3.2. Reimbursement Process
15.5.10. The South African Scenario
15.5.10.1. Regulatory Authority
15.5.10.2. Review / Approval Process
15.5.10.3. Reimbursement Landscape
15.5.11. The Taiwanese Scenario
15.5.11.1. Regulatory Authority
15.5.11.2. Review / Approval Process
15.5.11.3. Reimbursement Landscape
15.5.11.3.1. Payer Mix
15.5.11.3.2. Reimbursement Process
15.5.12. The Thailand Scenario
15.5.12.1. Regulatory Authority
15.5.12.2. Review / Approval Process
15.5.12.3. Reimbursement Landscape
15.6. Comparison of Regional Regulatory Environment
15.7. Concluding Remarks

16. MARKET SIZING AND OPPORTUNITY ANALYSIS
16.1. Chapter Overview
16.2. Forecast Methodology and Key Assumptions
16.3. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2020-2030 (By Value)
16.3.1. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2020-2030 (By Value)
16.3.2 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2020-2030 (By Value)
16.3.3 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2020-2030 (By Value)
16.4 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, 2020-2030 (By Value)
16.4.1 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, 2020-2030 (By Value)
16.4.2 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, 2020-2030 (By Value)
16.4.3 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, 2020-2030 (By Value)
16.5 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, 2020-2030 (By Value)
16.5.1 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, 2020-2030 (By Value)
16.5.2 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, 2020-2030 (By Value)
16.5.3 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, 2020-2030 (By Value)
16.6 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, 2020-2030 (By Value)
16.6.1 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, 2020-2030 (By Value)
16.6.2 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)
16.6.3 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, 2020-2030 (By Value)
16.7. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2020-2030 (By Volume)
16.7.1. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2020-2030 (By Volume)
16.7.2 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2020-2030 (By Volume)
16.7.3 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2020-2030 (By Volume)
16.8 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, 2020-2030 (By Volume)
16.8.1 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, 2020-2030 (By Volume)
16.8.2 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, 2020-2030 (By Volume)
16.8.3 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, 2020-2030 (By Volume)
16.9 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, 2020-2030 (By Volume)
16.9.1 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, 2020-2030 (By Volume)
16.9.2 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, 2020-2030 (By Volume)
16.9.3 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, 2020-2030 (By Volume)
16.1 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, 2020-2030 (By Value)
16.10.1 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, 2020-2030 (By Value)
16.10.2 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)
16.10.3 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, 2020-2030 (By Value)
16.11. Global Large Volume Wearable Injectors Market for Insulin, 2020-2030
16.11.1 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, 2020-2030
16.11.2 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, 2020-2030
16.12 Large Volume Wearable Injectors Market for Insulin in North America, 2020-2030
16.12.1 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Type of Device, 2020-2030
16.12.2 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Usability, 2020-2030
16.13 Large Volume Wearable Injectors Market for Insulin in Europe, 2020-2030
16.13.1 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Type of Device, 2020-2030
16.13.2 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Usability, 2020-2030
16.14 Large Volume Wearable Injectors Market for Insulin in Asia Pacific, 2020-2030
16.14.1 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Type of Device, 2020-2030
16.14.2 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Usability, 2020-2030

17. SWOT ANALYSIS
17.1. Chapter Overview
17.2. SWOT Analysis
17.2.1. Strengths
17.2.2. Weaknesses
17.2.3. Opportunities
17.2.4. Threats
17.3. Future Growth Opportunities

18. EXECUTIVE INSIGHTS
18.1. Chapter Overview
18.2. Medipacs
18.2.1. Company Snapshot
18.2.2. Interview Transcript: Mark Banister, Chief Executive Officer
18.3. Enable Injections
18.3.1. Company Snapshot
18.3.2. Interview Transcript: Michael Hooven, Chief Executive Officer
18.4. Subcuject
18.4.1. Company Snapshot
18.4.2. Interview Transcript: Jesper Roested, Chief Executive Officer
18.5. scPharmaceuticals
18.5.1. Company Snapshot
18.5.2. Interview Transcript: Pieter Muntendam, former President and Chief Executive Officer
18.6. Elcam Medical
18.6.1. Company Snapshot
18.6.2. Interview Transcript: Menachem Zucker, Vice President and Chief Scientist
18.7. West Pharmaceutical Services
18.7.1. Company Snapshot
18.7.2. Interview Transcript: Graham Reynolds, Vice President and General Manager, Biologics
18.8. Sorrel Medical
18.8.1. Company Snapshot
18.8.2. Interview Transcript: Mindy Katz, Director of Product

19. APPENDIX 1: TABULATED DATA

Note: Product cover images may vary from those shown
3 of 4
  • 3M
  • Abbott
  • AbbVie
  • AbGenomics
  • Ablynx
  • Acceleron Pharma
  • Accenture
  • Actavis Pharma
  • ADC Therapeutics
  • Adrenomed
  • Aduro Biotech
  • Advaxis
  • Aeglea BioTherapeutics
  • Aetna
  • Affibody
  • Affimed
  • Agenus
  • AgonOx
  • Akesobio Australia
  • Alder BioPharmaceuticals
  • Alector
  • Alexion Pharmaceuticals
  • Alkahest
  • Alkermes
  • Allakos
  • Allergan
  • Alnylam Pharmaceuticals
  • Allozyne
  • AlphaCore Pharma
  • Altor BioScience
  • Ambrx
  • amcure
  • Amgen
  • Amicus Therapeutics
  • Amphivena Therapeutics
  • Amplyx Pharmaceuticals
  • Angiochem
  • Antares Pharma
  • Antaros Medical
  • Apellis Pharmaceuticals
  • Aprea Therapeutics
  • Aptevo Therapeutics
  • argenx
  • Argos Therapeutics
  • ArmaGen
  • ARMO BioSciences
  • Aronora
  • Asante Solutions
  • Ascensia Diabetes Care
  • Asklepion Pharmaceuticals
  • Astorg Partners
  • Astellas Pharma
  • AstraZeneca
  • Atridia
  • Australasian Medical & Scientific
  • Axon Neuroscience
  • Baril
  • Basilea Pharmaceutica
  • Bastian Solutions
  • Battelle
  • Baxter International
  • Bayer
  • Bayhill Therapeutics
  • Becton Dickinson
  • BeiGene
  • Beijing Dongfang Biotech
  • Bespak
  • Beta Bionics
  • Bigfoot Biomedical
  • BioArctic
  • BIOCAD
  • Biogen
  • BioIntegrator
  • Bioject Medical Technologies
  • BioMarin Pharmaceutical
  • Bioniz Therapeutics
  • BioNTech
  • Bio-Path Holdings
  • Biotest Pharmaceuticals
  • Bio-Thera Solutions
  • Boehringer Ingelheim
  • Boston Pharmaceuticals
  • Bristol Myers Squibb
  • Bühler Motor
  • Calando Pharmaceuticals
  • Calibra Medical
  • Cam Med
  • CANbridge Life Sciences
  • Cancer Advances
  • Cara Therapeutics
  • Cardiome Pharma
  • Care Innovations
  • Catalyst Biosciences
  • Celgene
  • Celldex Therapeutics
  • CEL-SCI
  • CeQur
  • Chimerix
  • CHO Pharma
  • Chugai Pharmaceutical
  • Cleveland BioLabs
  • Conjupro Biotherapeutics
  • Consort Medical
  • ContraFect
  • ConvaTec
  • Cordant Group
  • Cour Pharmaceutical Development
  • CSL Behring
  • CStone Pharmaceuticals
  • CureTech
  • CytoDyn
  • Daikyo Seiko
  • Datwyler
  • Debiotech
  • DEKA
  • Dekkun
  • Delta-Fly Pharma
  • Dendreon
  • Dexcom
  • Diabeloop
  • DiaMedica Therapeutics
  • Diamyd Medical
  • DreaMed Diabetes
  • Duke University
  • E3D Elcam Drug Delivery Devices
  • European Connected Health Alliance (ECHAlliance)
  • EG-GILERO
  • Eisai
  • Eitan Group
  • Eli Lilly
  • Elusys Therapeutics
  • EMD Serono
  • Emergent BioSolutions
  • Enable Injections
  • Endocyte
  • EnGeneIC
  • EOFlow
  • EpicentRx
  • Eris Lifesciences
  • EVER Pharma
  • Evidation Health
  • F2G
  • Fabrico
  • Ferring Pharmaceuticals
  • FibroGen
  • Fitbit
  • Five Prime Therapeutics
  • Flex Pharma
  • Flex
  • Flowonix Medical
  • Fresenius Medical Care
  • Galaxy Biotech
  • Galena Biopharma
  • FedEx Supply Chain
  • Genentech
  • GENERON
  • GeneScience Pharmaceuticals
  • Genexine
  • Genzyme
  • Georgia Institute of Technology
  • Gerresheimer
  • Gilead Sciences
  • GlaxoSmithKline
  • Glenmark Pharmaceuticals
  • Gliknik
  • Glooko
  • Guangzhou Cellprotek Pharmaceutical
  • HAL Allergy
  • Halozyme Therapeutics
  • Hanmi Pharmaceutical
  • Harvard Pilgrim Health Care
  • Haselmeier
  • HealthPrize Technologies
  • Helsinn Healthcare
  • Hemispherx Biopharm
  • Hoffmann-La Roche
  • Huabo Biopharm
  • IBM Watson
  • International Diabetes Federation
  • ImClone Systems
  • Immatics Biotechnologies
  • Immune Response BioPharma
  • ImmunGene
  • Immunocore
  • ImmunoFrontier
  • ImmunoGen
  • Immunomedics
  • Immunotope
  • Immunovaccine
  • Implicit Bioscience
  • Incuron
  • Incyte
  • Innate Pharma
  • Innovent Biologics
  • Inovio Pharmaceuticals
  • Insulet
  • iNtRON Biotechnology
  • IO Biotech
  • Ionis Pharmaceuticals
  • Ipsen
  • iSense CGM
  • ISU ABXIS
  • Janssen
  • Jerini
  • JHL Biotech
  • Jiangsu Hengrui Medicine
  • Jiangsu T-Mab Biopharma
  • Johnson & Johnson
  • Jounce Therapeutics
  • Juvenile Diabetes Research Foundation
  • KaloBios Pharmaceuticals
  • Kiniksa Pharmaceuticals
  • Kissei Pharmaceutical
  • Klue
  • Kura Oncology
  • Kyowa Hakko Kirin
  • Labrys Biologics
  • LEO Pharma
  • Levicept
  • Life Science Pharmaceuticals
  • MabVax Therapeutics
  • MacroGenics
  • Massachusetts Institute of Technology
  • MedImmune
  • Medimop Medical Projects
  • Medipacs
  • Medtronic
  • Medtrum Technologies
  • Menarini Diagnostics
  • Menarini Group
  • Merck
  • Merck Sharp & Dohme
  • Mercy Technology Services
  • Mereo BioPharma
  • Merrimack Pharmaceuticals
  • Mersana Therapeutics
  • Merus
  • Merz Pharma
  • Millennium Pharmaceuticals
  • MiNA Therapeutics
  • miRagen Therapeutics
  • Mitsubishi Tanabe Pharma
  • Mode AGC (Automated Glucose Control)
  • Moderna Therapeutics
  • Molecular Partners
  • Molecular Templates
  • MolMed
  • Montagu Private Equity
  • MorphoSys
  • Morphotek
  • Movi
  • MTD Micro Molding
  • mySugr
  • NanoPass Technologies
  • NantBioScience
  • Naurex
  • Navidea Biopharmaceuticals
  • Nemera
  • Neogenix Oncology
  • Neon Therapeutics
  • NeuroDerm
  • New Zealand Medical & Scientific
  • Noble
  • Nordic Bioscience
  • Nordic Infucare
  • Northern Biologics
  • Novartis Pharmaceuticals
  • Novimmune
  • NOVO Engineering
  • Novo Nordisk
  • OBI Pharma
  • Octapharma
  • Omeros
  • Oncology Venture
  • OncoMed Pharmaceuticals
  • OncoPep
  • Oncopeptides
  • Oncternal Therapeutics
  • Oncurious
  • Opthea
  • Optimer Pharmaceuticals
  • OSE Immunotherapeutics
  • Otsuka Pharmaceutical
  • Owen Mumford
  • Paion UK
  • Panacea Biotec
  • PercuSense
  • Pfizer
  • PharmaJet
  • PharmaMar
  • PharmaSens
  • PhaseBio Pharmaceuticals
  • Phillips-Medisize
  • Philogen
  • Phosplatin Therapeutics
  • Pierre Fabre
  • Pique Therapeutics
  • Polaris Group
  • Polyphor
  • Prescient Therapeutics
  • Prestige BioPharma
  • Promedior
  • Prometheus Laboratories
  • Protalix Biotherapeutics
  • Proven Process Medical Devices
  • Pulmonary Hypertension Association
  • Qualcomm
  • Quest PharmaTech
  • Quintessence Biosciences
  • Ratio Drug Delivery
  • RAUMEDIC
  • Recro Pharma
  • Recipharm
  • Regeneron Pharmaceuticals
  • REM Systems
  • REMD Biotherapeutics
  • Resolve Therapeutics
  • rEVO Biologics
  • Rhythm Pharmaceuticals
  • Roche
  • Roehr pharmaceuticals
  • R-Pharm
  • Rubin Medical
  • RxActuator
  • Sagentia
  • Samsung Bioepis
  • Sandoz
  • Sanofi
  • Santarus
  • Saol Therapeutics
  • Savient Pharmaceuticals
  • scPharmaceuticals
  • Seattle Genetics
  • Selecta Biosciences
  • Selexys Pharmaceuticals
  • Sensile Medical
  • Serina Therapeutics
  • SFC Fluidics
  • Shire
  • SHL Medical
  • Singularity University
  • SMC Global
  • Smiths Medical
  • Sonceboz
  • SOOIL Development
  • SPARK Strategic Ideas
  • SQ Innovation
  • SteadyMed Therapeutics
  • Stealth BioTherapeutics
  • Stemline Therapeutics
  • Stevanato Group
  • Subcuject
  • Sumitomo Dainippon Pharma
  • Sunovion Pharmaceuticals
  • Swissfillon
  • SymBio Pharmaceuticals
  • Symphogen
  • Synectics
  • Synermore Biologics
  • Syntimmune
  • Syros Pharmaceuticals
  • TaiMed Biologics
  • Taiwan Liposome Company
  • Takeda Pharmaceutical
  • Tandem Diabetes Care
  • Tanvex BioPharma
  • Tarveda Therapeutics
  • Teva Pharmaceutical
  • TG Therapeutics
  • Theras Lifetech
  • Tidepool
  • Tolero Pharmaceuticals
  • TRACON Pharmaceuticals
  • Translational Sciences
  • Turnstone Biologics
  • Tyndall National Institute
  • TypeZero Technologies
  • Union Chimique Belge (UCB)
  • United BioPharma
  • United Therapeutics
  • University of Arizona
  • University of Bern
  • University of Colorado
  • University of Hertfordshire
  • University of Virginia
  • Vaccinex
  • Vaccinogen
  • Valtronic
  • vasopharm BIOTECH
  • Verily Life Sciences
  • Vetter Pharma
  • ViCentra
  • ViiV Healthcare
  • Visterra
  • Vivozon
  • Weibel CDS
  • West Pharmaceutical Services
  • Wockhardt
  • XBiotech
  • Xencor
  • XOMA
  • Ypsomed
  • Zafgen
  • Zealand Pharma
  • Zollner
  • Zuellig Pharma
Note: Product cover images may vary from those shown
4 of 4

 

 

Loading
LOADING...

Adroll
adroll